BioInItaly Newsletter

La vetrina del biotech italiano all’estero

N.4_2018/ NEWSLETTER MENSILE

22 mag, 2018

Novartis and Amgen announce FDA approval of Aimovig™ (erenumab), a novel treatment developed specifically for migraine prevention
Novartis announces that the US Food and Drug Administration (FDA) has approved AimovigTM (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector and does not require a loading dose. More info: https://novartis.gcs-web.com/Novartis-and-Amgen-announce-FDA-approval-of-Aimovig-erenumab-a-novel-treatment-developed-specifically-for-migraine-prevention

Acousia Therapeutics Announces 10 Million euros Series B Financing to Advance its Hearing Loss Portfolio
Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to develop therapies for the treatment of hearing loss, raised €10 Million in Series B Financing round. The financing was led by new investor LBBW Venture Capital, and joined by other new investors, Creathor Ventures and Bregua Corporation. Existing investors, Boehringer Ingelheim Venture Fund (BIVF) and Kreditanstalt für Wiederaufbau (KfW) also participated in the round. More info: http://www.axxam.com/sites/default/files/uploads/news/attachments/235/pracousia180514.pdf.


EryDel Raises 26.5 Million euros in Financing

EryDel SpA, a biotech company specialized in drug delivery through red blood cells, announces the closing of a Euro 26.5 million financing led by Sofinnova Partners, with existing investors, Genextra SpA and Innogest SGR also participating. In conjunction with the financing, Sofinnova Partners’ Managing Partner Graziano Seghezzi, has joined EryDel’s Board of Directors. 
More info: http://www.erydel.com/public/sitemin/EryDel_raises_26.5_Euro_financing.pdf.

MolMed signs Master Service Agreement with Boston Children’s Hospital for the supply of lentiviral vectors 
MolMed S.p.A., medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, announces the signing of a five years Master Service Agreement, and a related first Project Agreement, with Boston Children’s Hospital for the production of lentiviral vectors to be used for clinical application in rare diseases. 
Boston Children’s Hospital is one of the most relevant pediatric healthcare center worldwide for care and treatment of complex diseases. Thanks to its affiliations, including Harvard Medical School, Boston Children’s Hospital can guarantee to hospital patients an unparalleled access to the latest science and technology. More info: http://www.molmed.com/sites/default/files/uploads/press-releases/3321/3321_1525414127.pdf

Chiesi Group receives the European Marketing Authorisation for Lamzede® (velmanase alfa) 
Chiesi, an international research-focussed healthcare group, announces that the European Commission has granted the marketing authorisation for Lamzede® (velmanase alfa), the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha mannosidosis (AM), an ultra-rare progressive and debilitating disease1. As a result of this marketing authorisation, Velmanase alfa is now approved for use in the 31 European countries covered by the European Medicines Agency (EMA). More info: http://www.chiesi.com/en/chiesi-group-receives-the-european-marketing-authorisation-for-lamzedevelmanase-alfa/